LAVA Therapeutics Prepares for H.C. Wainwright Conference 2024
LAVA Therapeutics Prepares for H.C. Wainwright Conference 2024
UTRECHT, The Netherlands and PHILADELPHIA – LAVA Therapeutics N.V. (NASDAQ: LVTX), a pioneering clinical-stage immuno-oncology firm, is excited to announce its participation in the H.C. Wainwright 26th Annual Global Investment Conference. This event serves as a platform for ongoing medical advancements and investment opportunities.
Presentation Details
Stephen Hurly, the Chief Executive Officer of LAVA Therapeutics, will deliver a presentation format described as a fireside chat. Scheduled for Monday, this insightful session will commence at 3:30 PM ET, allowing attendees to gain insight into the company’s cutting-edge strategies and future directions. The presentation will be accessible for viewing via the company’s investor relations webpage.
Investors and interested parties can catch the replay of this presentation, which will be available for up to 90 days post-event. The company encourages everyone to visit their investor relations section for updates and details on future events.
About LAVA Therapeutics and Their Innovations
LAVA Therapeutics N.V. is dedicated to transforming the landscape of cancer treatment through its proprietary Gammabody platform, focusing on bispecific gamma-delta T cell engagers. These innovative therapies aim to target and eradicate a variety of solid tumors and hematologic cancers.
Ongoing Clinical Research
Currently, LAVA is actively recruiting participants for a Phase 1 dose escalation study (NCT05369000) aimed at evaluating LAVA-1207. This ambitious project focuses on patients with metastatic castration-resistant prostate cancer (mCRPC) and explores both monotherapy and treatments in conjunction with interleukin-2 (IL-2). Moreover, an exciting development is the expansion of this Phase 1 study to incorporate a combination approach with KEYTRUDA® (pembrolizumab) through a collaborative effort with Merck & Co., Inc.
Strategic Collaborations and Licensing
LAVA has also made notable strides in its business operations. The company has entered into a licensing agreement for PF-08046052 (previously known as LAVA-1223) with Pfizer Inc., aimed at further clinical development and commercialization. This partnership, along with several pre-clinical programs, showcases LAVA's commitment to advancing immune-oncology therapies.
Empowering Cancer Care
The Gammabody platform stands out as a symbol of innovation, designed to harness the specific immune response of gamma-delta T cells against tumors. By engaging these immune cells effectively, the goal is to provide patients with more targeted and efficient therapies.
Frequently Asked Questions
What is the focus of LAVA Therapeutics?
LAVA Therapeutics specializes in developing immuno-oncology therapies, particularly focusing on their Gammabody platform of bispecific gamma-delta T cell engagers.
When is the H.C. Wainwright Conference?
The 26th Annual Global Investment Conference is scheduled for Monday, with Stephen Hurly presenting at 3:30 PM ET.
Where can I watch the presentation?
The presentation will be available on the investor relations section of the LAVA Therapeutics website.
What is the company’s lead program?
The lead program at LAVA is LAVA-1207, which is currently in a Phase 1 clinical trial for metastatic castration-resistant prostate cancer.
Who can provide more information about LAVA Therapeutics?
For more inquiries, interested parties can contact Investor Relations at ir@lavatherapeutics.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Baker Hughes Unveils Leadership Changes for Future Growth
- Citi Predicts 125,000 Jobs in NFP, Foresees Fed Rate Cut
- Former Central Bank Governor Riad Salameh Faces Arrest Over Fraud
- UK Home Prices Expected to Rise, Boosting First-Time Buyer Affordability
- US Dollar Index Emerges as Key Factor for European Markets
- Constellation Brands Adjusts Earnings Outlook for 2025
- Corporate Profit Challenges: Earnings Outlook for 2025
- Opus Technologies Introduces Paysemble™ for Payment Solutions
- DMEX.APP Launches Cross Margin Positions for Traders
- Blue Federal Credit Union Achieves Prestigious Awards in 2024
- Global NGS Sample Preparation Market Poised for Growth
- Assisted Living Locators' Inspiring Initiative for Alzheimer's Month
- Bevel Becomes Official Grooming Sponsor for CAU Alumni Event
- Executive Home Care Promotes Fall Prevention Awareness for Seniors
- Light The Night: Illuminate Hope for Blood Cancer Patients
- Cambridge Launches Family Business Leadership Programme in 2024
- Allpowers Showcases Innovative Power Solutions at IFA 2024
- Growing Demand for Pick to Light Solutions Transforming Industries
- TEN, Ltd. Schedules Q2 2024 Results Event and Conference Call
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- Coloplast A/S Share Trading Insights for Board and Executives
- BW Offshore Adjusts Convertible Bonds for Shareholders' Dividend
- Procaps Group Outlines Strategic Vision for Future Success
- CenExel Launches Advanced PET Scan Unit for Research
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
Recent Articles
- Citi Predicts 125,000 Jobs in NFP, Foresees Fed Rate Cut
- Corporate Profit Challenges: Earnings Outlook for 2025
- DMEX.APP Launches Cross Margin Positions for Traders
- Park Street A/S Announces Treasury Shares Update
- Decisely Proudly Partners with Stewart-Haas Racing in NASCAR
- Nutricosmetics Market Expected to Exceed $16.93 Billion Growth
- Weatherford Strengthens Digital Portfolio with Datagration Deal
- Century Lithium Reports High Purity Lithium Carbonate Results
- Growth of Medical Tourism Market Forecast to USD 207.5 Billion
- Navigating Risks for Bullish Investors this September
- DSV A/S Launches Major Share Buyback Program Announcement
- Spectral Medical Updates on Progress of Tigris Trial
- NCL Corporation Ltd. Proposes Offering of Senior Notes
- Soligenix Secures European Patent for Synthetic Hypericin Production
- Elevation Oncology Highlights Upcoming H.C. Wainwright Conference
- ATI Initiates $700 Million Share Repurchase Program
- ADC Therapeutics Announces Conference Presentations in September
- Cartesian Therapeutics Begins Clinical Trial of Descartes-15
- Exploring the Growth of the Amphoteric Surfactants Market
- Eyenovia Appoints Andrew Jones as Chief Financial Officer
- Aviation Safety Summit 2024: Leaders In Safety Innovations
- HSG Laser Celebrates Four Years of Innovation and Growth
- MacroGenics, Inc. Investors Encouraged to Contact Legal Team
- Skyecap Achieves 500% Growth: A New Era for SMEs
- Markel Welcomes Rhys O'Neill as Senior Underwriter in Marine